Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Treatment of progressive multiple sclerosis: What works, what does not, and what is needed
(2022) demonstrated Cerebrolysin's effects on Alzheimer's disease biomarkers in a randomized controlled trial, providing objective biological evidence for its neurotrophic activity (PMID: 36155516) Regulatory Validation: Approved for clinical use in over 40 countries for indications including stroke, traumatic brain injury, and dementia (though not FDA-approved in the United States) Dihexa: Preclinical Only, with Integrity Concerns Dihexa's evidence base is entirely preclinical and has faced significant scientific integrity challenges: Foundational Research: Wright et al
Complete recovery may take 6-12 months, depending on the severity of the damage and individual factors
Checkout was simple and order confirmation was received immediately
However, research is still ongoing, and results may vary
US$ 22.65
US$ 22.64
US$ 20.01
US$ 24.01
US$ 23.05
